Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematopoietic and Lymphoid Cell Neoplasm: early-phase trial registry
35 of 105 indexed Hematopoietic and Lymphoid Cell Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #125 of 28,707 conditions by registered trial count.
105 US clinical trials · 35 currently recruiting · #125 of 28,707 conditions by registered trial count
Hematopoietic and Lymphoid Cell Neoplasm: 105 US clinical trials tracked, 35 recruiting.
Hematopoietic and Lymphoid Cell Neoplasm is the subject of 105 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 44 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 44 of these trials.
Enrollment posture brief
Registry condition hematopoietic-and-lymphoid-cell-neoplasm
OPEN 35 | RECR 33% | LATE 8 | EARLY 44 | RANK #125 | SPON 44
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Hematopoietic and Lymphoid Cell Neoplasm lists 35 open slots (33% of 105 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematopoietic and Lymphoid Cell Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematopoietic and Lymphoid Cell Neoplasm is recruiting below its size-band peers.
35 of 105 indexed trials (33.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematopoietic and Lymphoid Cell Neoplasm research.
M.D. Anderson Cancer Center accounts for 44 of 105 trials (41.9%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematopoietic and Lymphoid Cell Neoplasm enrolment sits around 72 participants.
Median target enrolment is 72 among the 105 trials that report a genuine target (sentinel values excluded). 57 of those (54.3%) plan for fewer than 100 participants.
-
Hematopoietic and Lymphoid Cell Neoplasm research is mostly interventional.
74 interventional and 31 observational studies make up this index (70.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
105 total, page 2 of 3
Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
M.D. Anderson Cancer Center
NCT04188418
Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors
City of Hope Medical Center
NCT05138991
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
University of Rochester NCORP Research Base
NCT04888988
Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer
M.D. Anderson Cancer Center
NCT05055011
Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic
M.D. Anderson Cancer Center
NCT05102656
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
Academic and Community Cancer Research United
NCT05246670
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
M.D. Anderson Cancer Center
NCT04296305
Vincristine Pharmacokinetics in Infants
Children's Oncology Group
NCT05359237
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT02530034
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
NCT04439175
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
M.D. Anderson Cancer Center
NCT01628029
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
NCT04439344
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center
NCT04198922
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
NCT04439318
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
M.D. Anderson Cancer Center
NCT02210078
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03023631
Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)
M.D. Anderson Cancer Center
NCT02515383
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
NCT04439136
A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation
City of Hope Medical Center
NCT04914338
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
NCT04439201
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
National Cancer Institute (NCI)
NCT02862275
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
NCT04439110
Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians
M.D. Anderson Cancer Center
NCT04196972
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT03922035
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
NCT04439227
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
NCT04439331
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
NCT04439188
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
NCT04439279
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
NCT04439123
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
NCT04439292
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT03399773
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Ohio State University Comprehensive Cancer Center
NCT05972577
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT04459273
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
NCT04439149
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
City of Hope Medical Center
NCT05173961
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
City of Hope Medical Center
NCT05023993
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
NCT06303167
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT02993146
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
NCT04745910
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
NCT04439253
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
NCT04439357
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
M.D. Anderson Cancer Center
NCT04743466
Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial
Mayo Clinic
NCT03892967
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
M.D. Anderson Cancer Center
NCT05045963
Perioperative Care in the Cancer Patient -1, ARCA-1 Study
M.D. Anderson Cancer Center
NCT04491409
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer
M.D. Anderson Cancer Center
NCT05058339
Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment
Thomas Jefferson University
NCT04788758
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
National Cancer Institute (NCI)
NCT01039155
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 28 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematopoietic and Lymphoid Cell Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematopoietic and Lymphoid Cell Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematopoietic and Lymphoid Cell Neoplasm page
105 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Hematopoietic and Lymphoid Cell Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Hematopoietic and Lymphoid Cell Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematopoietic and Lymphoid Cell Neoplasm condition card totals 105 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.